GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Genomic Health, Inc. (GHDX) [hlAlert]

Rating:
Buy GHDX
down 11.69 %

Genomic Health, Inc. (GHDX) rated Buy with price target $38 by UBS

Posted on: Monday,  Nov 23, 2015  10:25 AM ET by UBS

UBS rated Buy Genomic Health, Inc. (NASDAQ: GHDX) on 11/23/2015, when the stock price was $30.27. Since
then, Genomic Health, Inc. has lost 11.69% as of 01/06/2016's recent price of $26.73.
If you would have followed this UBS's recommendation on GHDX, you would have lost 11.69% of your investment in 44 days.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/23/2015 10:25 AM Buy
None
30.27 38.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy